CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

about

What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives

P2860

Q57159608-0316C6A7-13DC-409D-9C35-9E3D3896196A

P2860

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

Item

http://www.wikidata.org/entity/Q58775775

description

im Oktober 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

CheckMate-032 Study: Efficacy ...... astatic Esophagogastric Cancer

@en

CheckMate-032 Study: Efficacy ...... astatic Esophagogastric Cancer

@nl

type

Item

label

CheckMate-032 Study: Efficacy ...... astatic Esophagogastric Cancer

@en

CheckMate-032 Study: Efficacy ...... astatic Esophagogastric Cancer

@nl

prefLabel

CheckMate-032 Study: Efficacy ...... astatic Esophagogastric Cancer

@en

CheckMate-032 Study: Efficacy ...... astatic Esophagogastric Cancer

@nl

P1476

CheckMate-032 Study: Efficacy ...... astatic Esophagogastric Cancer

@en

P2093

Cecile Dorange

http://www.w3.org/2001/XMLSchema#string

Christopher T Harbison

http://www.w3.org/2001/XMLSchema#string

Dirk Jaeger

http://www.w3.org/2001/XMLSchema#string

Dung T Le

http://www.w3.org/2001/XMLSchema#string

Emiliano Calvo

http://www.w3.org/2001/XMLSchema#string

Filippo de Braud

http://www.w3.org/2001/XMLSchema#string

Ian Chau

http://www.w3.org/2001/XMLSchema#string

Jeffry Evans

http://www.w3.org/2001/XMLSchema#string

Johanna Bendell

http://www.w3.org/2001/XMLSchema#string

Joseph W Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability

Nivolumab plus ipilimumab in advanced melanoma.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Comprehensive molecular characterization of gastric adenocarcinoma

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients.

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.

P304

2836-2844

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2017.76.6212

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Paolo Antonio Ascierto

P577

2018-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30110194

http://www.w3.org/2001/XMLSchema#string

P921

cancer research

P932

6161834

http://www.w3.org/2001/XMLSchema#string

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

about

P2860

P2860

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932